noom vs hers glp 1 Noom: Approach, Pricing, Compounded Pathway noom is pushing deeper into

Thats exactly why Novo Nordisk combined cagrilintide with semaglutide in CagriSemathe idea is that hitting both the amylin and GLP-1 pathways together could produce greater effects than either one alone

This allows for deeper study of pathway-specific activity without the confounding effects of poly-compound blends

The most common side effects of these drugs are mild gastrointestinal (GI) issues

However, with massive demand comes massive responsibility

10.1016/j.neuron.2011.12.002 Neuron 186 Louis-SylvestreJ

Drawing from PSGs 2025 Trends in Drug Benefit Design Report, this webinar provides essential insights for benefits professionals navigating the complex landscape of GLP-1 coverage decisions